Extrawell Pharmaceutical Holdings Valuation

Is 858 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 858 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 858's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 858's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 858?

Key metric: As 858 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 858. This is calculated by dividing 858's market cap by their current revenue.
What is 858's PS Ratio?
PS Ratio	2.2x
Sales	HK$59.10m
Market Cap	HK$129.06m

858 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.6x
Enterprise Value/EBITDA	210.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 858's PS Ratio compare to its peers?

The above table shows the PS ratio for 858 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.5x
1312 Kontafarma China Holdings	0.2x	n/a	HK$173.2m
897 Wai Yuen Tong Medicine Holdings	0.3x	n/a	HK$236.3m
1643 Modern Chinese Medicine Group	1x	n/a	HK$249.0m
1498 PuraPharm	0.6x	n/a	HK$252.8m
858 Extrawell Pharmaceutical Holdings	2.2x	n/a	HK$129.1m

Price-To-Sales vs Peers: 858 is expensive based on its Price-To-Sales Ratio (2.2x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does 858's PS Ratio compare vs other companies in the HK Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
3320 China Resources Pharmaceutical Group	0.1x	8.0%	US$4.18b
8329 Shenzhen Neptunus Interlong Bio-technique	0.2x	n/a	US$29.96m
1312 Kontafarma China Holdings	0.2x	n/a	US$22.26m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 858 is expensive based on its Price-To-Sales Ratio (2.2x) compared to the Hong Kong Pharmaceuticals industry average (1.4x).

Price to Sales Ratio vs Fair Ratio

What is 858's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

858 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 858's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

3SBio

HK$13.0b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.52

-4.3%

-26.2%

China Shineway Pharmaceutical Group

HK$6.1b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.13

-3.3%

n/a